Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer

Association of tumor infiltration lymphocytes and complete pathological response in breast cancer patients under neoadjuvant chemotherapy

Background: The breast cancer is the most common type of cancer in Iran. Hence determination of the optimal treatment and the contributing factors are important. The main aim in current study was to determine the association between tumor infiltration of lymphocytes (TIL) and complete pathological response in breast cancer patients after neoadjuvant chemotherapy. Methods and materials: In this...

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer

Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC). pCR in this setting is associated with improved EFS. Whether NCT preferentially improves EFS in comparison to NC followed by adjuvant trastuzumab initiated postoper...

Neoadjuvant Chemotherapy for Breast Cancer

Aminoacyl-tRNA Synthetase Complexes in Evolution

Aminoacyl-tRNA synthetases are essential enzymes for interpreting the genetic code. They are responsible for the proper pairing of codons on mRNA with amino acids. In addition to this canonical, translational function, they are also involved in the control of many cellular pathways essential for the maintenance of cellular homeostasis. Association of several of these enzymes within supramolecul...

Changes in Cytokeratin 18 during Neoadjuvant Chemotherapy of Breast Cancer: A Prospective Study

Background & Objective: Premalignant lesions of cervix have increased dramatically in recent years. Early diagnosis and management of abnormalitie...